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Introduction: There is a mechanism of macrolide resistance in Staphylococcus spp. which also
affects the lincosamides and type B streptogramins characterizing the so-called MLSB resis-
tance, whose expression can be constitutive (cMLSB) or inducible (iMLSB) and is encoded
mainly by ermA and ermC genes. The cMLSB resistance is easily detected by susceptibility
testing used in the laboratory routine, but iMLSB resistance is not. Therapy with clindamycin
in  cases of infection with isolated iMLSB resistance may fail.
Objective: To characterize the phenotypic (occurrence of cMLSB and iMLSB phenotypes) and
molecular (occurrence of ermA and ermC genes) proﬁles of MLSB resistance of clinical isolates
of  susceptible and methicillin-resistant Staphylococcus aureus and CNS (coagulase-negative
Staphylococcus)  from patients of a university hospital, in Pernambuco.
Methods: The antimicrobial susceptibility of 103 isolates was determined by the disk diffu-
sion technique in Mueller–Hinton agar followed by oxacillin screening. The iMLSB phenotype
was detected by D test. Isolates with cMLSB and iMLSB phenotypes were subjected to poly-
merase chain reaction (PCR) for the detection of ermA and ermC genes.
Results: The cMLSB and iMLSB phenotypes were respectively identiﬁed in 39 (37.9%) and ﬁve
(4.9%) isolates. The iMLSB phenotype was found only in four (10.8%) methicillin-susceptible
S.  aureus and one (4.5%) methicillin-resistant S. aureus. In the 44 isolates subjected to PCR,
four (9.1%) only ermA gene was detected, a lower frequency when compared to only ermC 17
(38.6%) gene and to one (2.3%) isolate presenting both genes.
Conclusion: In the Staphylococcus spp. analyzed, the ermC gene was found more often thanthe ermA, although the iM
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of 25 L for each tube and includes: 1 L (40 ng) of total DNA,b r a z j i n f e c t d i s .
ntroduction
The increasing prevalence of methicillin resistance in
taphylococcus spp. is a growing problem. This has renewed
nterest regarding the use of macrolide, lincosamides, and
ype B streptogramin antimicrobials for the treatment of
taphylococcal infections. Clindamycin, a lincosamide, rep-
esents a common choice for some of these infections,
articularly for infections of the skin and soft tissues, and
n alternative in case of intolerance to penicillin or methi-
illin resistance.1–3 In Staphylococcus spp., one of the resistance
echanisms consists of ribosomal target modiﬁcation,
ffecting macrolides, lincosamides, and type B streptogramins
haracterizes the so-called MLSB resistance. Its expression
an be constitutive (cMLSB) or inducible (iMLSB) and is
ncoded by ermA (erythromycin ribosome methylase) and
rmC genes, which are the main determinants of resistance in
taphylococci.2,4,5
It is important to know the type of MLSB resistance
or establishing adequate therapy, since Staphylococcus spp.
ith constitutive resistance present in vitro resistance to
ll macrolides, lincosamides, and type B streptogramins.
n addition, in vivo therapy with clindamycin for Staphy-
ococcus spp. infection with inducible resistance can select
onstitutive erm mutants, resulting in treatment failure.3,4,6,7
t is noteworthy that cMLSB resistance is easily detected
y susceptibility testing used in the laboratory routine,
hile iMLSB resistance is not. Using these detection
ethods, Staphylococcus spp. with inducible resistance has
n vitro resistance to erythromycin and susceptibility to
lindamycin.5,6,8,9
To detect the inducible clindamycin resistance in Staphy-
ococcus spp., one of the tests recommended by the CLSI
Clinical and Laboratory Standards Institute) is the double-
isk diffusion test (D Test) and when the isolated present such
esistance, the CLSI recommends reporting them as resistant
o clindamycin.10 Then, data on the antimicrobial susceptibil-
ty are important in the choice of therapy against infections,
ut false susceptibility results can be obtained if the isolates
re not subjected to tests that detect inducible resistance to
lindamycin.11
Studies carried out in two Brazilian states with clinical
solates of Staphylococcus spp. reported the cMLSB phenotype
s the most frequent.12,13 Coutinho et al.13 have also eval-
ated the occurrence of the erm genes among the isolates
nalyzed. However, the frequency of cMLSB and iMLSB resis-
ance varies among different hospitals and there are other
esistance mechanisms that confer resistance to only one or
wo classes of the MLSB complex.14,15
The objective of this study was to characterize the
henotypic (occurrence of cMLSB and iMLSB phenotypes)
nd molecular (occurrence of ermA and ermC genes) pro-
les of MLSB resistance of clinical isolates of susceptible
nd methicillin-resistant Staphylococcus aureus and CNS
coagulase-negative Staphylococcus)  from patients of a uni-
ersity hospital in Pernambuco, Brazil. Obtaining local data
elating to resistance, may be helpful in guiding therapeutic
pproaches.6;2 0(3):276–281 277
Materials  and  methods
Clinical  isolates
A total of 103 clinical isolates were gathered from various sam-
ples from patients infected with S. aureus or SCN of a university
hospital of Pernambuco, Brazil, during the year 2012 and were
stored in glycerol (25%) at −20 ◦C. To verify the purity, the
colonies were inoculated into Brain Heart Infusion broth (BHI)
and after incubation at 37 ◦C for 48 h were plated on blood agar.
Antimicrobial  susceptibility  proﬁle
The antibiogram was performed by disk diffusion technique in
Mueller–Hinton agar, using antibiotic clindamycin 2 g, eryth-
romycin 15 g, cefoxitin 30 g, and oxacillin 1 g. The results
were interpreted according to the standards determined by
CLSI.10
Screening  for  oxacillin  resistance
Isolates with resistance or intermediate resistance to oxacillin
and/or cefoxitin were submitted to oxacillin screening, as pro-
posed by Rabelo et al.16
D  test
S. aureus and SCN isolates with resistance to erythromycin
and susceptibility or intermediate resistance to clindamycin
in the antibiogram were selected. For the execution of this
test a disk of 2 g of clindamycin was placed at a distance of
15 mm–26 mm from the edge of a disk of 15 g of erythromycin
in a plate containing Mueller–Hinton agar sown  in the same
way as it was for the antibiogram. After incubation at 35 ◦C for
16–18 h, isolates that showed no ﬂattening of the inhibition
zone around the clindamycin disk were reported as suscepti-
ble to clindamycin (negative D test) and isolates that showed
ﬂattening of the inhibition zone around the clindamycin disk
adjacent to erythromycin disk (“D” zone) indicated inducible
clindamycin resistance (positive D test).10
Extraction  of  total  DNA
To examine the presence of ermA and emrC genes, the rapid
extraction of the total DNA of isolates that showed phenotypes
MLSBc and MLSBi was performed by a modiﬁed technique of
thermal lysis directly from the colony, according to Hu et al.,17
after inoculation of a colony of each isolate into 5 mL of BHI
and incubated at 37 ◦C for 24 h.
Polymerase  chain  reaction  (PCR)  conditions
PCR was performed using the primers described by Lina et al.18
for ermA and ermC genes. For the detection of ermA gene,
each ampliﬁcation reaction was prepared in a ﬁnal volume1 L (20 pmol) of each primer, 0.6 L of deoxyribonucleotide
triphosphate (dNTP) (8 mM), 5.0 L of buffer (5×), 1.5 L of
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Table 1 – Susceptibility proﬁle to erythromycin and clindamycin of susceptible and methicillin-resistant S. aureus and
CNS.
Phenotypes MSSA
n (%)
MRSA
n  (%)
MSCNS
n  (%)
MRCNS
n  (%)
Total
n  (%)
ERY-S, CLI-S (susceptible) 25 (67.6) 5 (22.7) 4 (28.6) 7 (23.3) 41 (39.8)
ERY-S, CLI-I 1 (2.7) 0 (0) 1 (7.1) 0 (0) 2 (1.9)
ERY-S, CLI-R 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
ERY-I, CLI-S 1 (2.7) 0 (0) 2 (14.3) 0 (0) 3 (2.9)
ERY-I, CLI-I 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
ERY-I, CLI-R 0  (0) 0  (0) 0 (0) 1  (3.3) 1  (1)
ERY-R, CLI-R (cMLSB) 4  (10.8) 15 (68.2) 3 (21.4) 17 (56.7) 39 (37.9)
ERY-R, CLI-S/I, + D Test (iMLSB) 4  (10.8) 1 (4.5) 0 (0) 0 (0) 5 (4.9)
ERY-R, CLI-S/I, – Test D (MSB) 2 (5.4) 1 (4.5) 4 (28.6) 5 (16.7) 12 (11.6)
Total 37 (35.9) 22 (21.4) 14 (13.6) 30 (29.1) 103 (100)
ERY, erythromycin; CLI, clindamycin; S, susceptible; I, intermediary; R, resistant; MSSA, methicillin-susceptible Staphylococcus aureus; MRSA,
methicillin-resistant S. aureus; MSCNS, methicillin-susceptible coagulase-negative Staphylococcus;  MRCNS, methicillin-resistant coagulase-
treptogramins; cMLSB, phenotype of constitutive MLSB resistance; iMLSB,
e to macrolides and type B streptogramins.
Fig. 1 – Positive D test, showing the ﬂattening of the
inhibition zone around the clindamycin disk adjacent tonegative Staphylococcus;  MLSB, macrolides, lincosamides and type B s
phenotype of inducible MLSB resistance; MSB, phenotype of resistanc
MgCl2 (25 mM),  0.4 L of Taq DNA polymerase (5U). For the
detection of ermC gene, each ampliﬁcation reaction was pre-
pared in the same manner as for ermA gene, except in relation
to the quantity of Taq DNA polymerase (5U), which in this reac-
tion was 0.3 L. Ampliﬁcation reactions were performed in the
thermocycler at the following conditions: 30 cycles of 1 min  at
94 ◦C in the denaturing step, 30 s at 49 ◦C in the annealing step
and 30 s at 72 ◦C in the extension step, according to the condi-
tions described by Franc¸a et al.19 with modiﬁcation. In all PCR
a negative control was included, corresponding to a tube con-
taining all components of the mixture to which template DNA
was not added. Identiﬁed positive isolates for the ermA and
ermC genes were used as positive controls. The PCR products
were subjected to electrophoresis on 1.5% agarose gel in 0.5×
TBE buffer. These products were stained with blue, visualized
on an ultraviolet transilluminator and photodocumented.
Sequencing  of  ermA  and  ermC  genes
A PCR product positive for the ermA and ermC genes were
puriﬁed through the kit Wizard® SV Gel and PCR Clean-Up
System (Promega), according to manufacturer’s protocol and
then, quantiﬁed by spectrophotometry. Thereafter they were
submitted to sequencing and analysis of the results was per-
formed through the softwares Chromas Lite 2.1.1, Basic Local
Alignment Search Tool (BLAST), and Expert Protein Analy-
sis System (ExPASy). The analyzed sequences of ermA and
ermC genes were deposited in the GenBank with the following
access numbers, respectively: KT599443 and KU232395.
Results
Fifty-nine (57.3%) clinical isolates of S. aureus and 44 (42.7%)
of SCN were analyzed, totaling 103 isolates. Of these, 37
(35.9%), 22 (21.4%), 14 (13.6%), and 30 (29.1%) were classiﬁed as
methicillin-susceptible S. aureus (MSSA), methicillin-resistant
S. aureus (MRSA), methicillin-susceptible coagulase-negative
Staphylococcus (MSCNS) and methicillin-resistant coagulase-
negative Staphylococcus (MRCNS), respectively (Table 1).erythromycin disk (called “D” zone).
The susceptible phenotype (ERY-S, CLI-S) was detected in 25
(67.6%), ﬁve (22.7%), four (28.6%), and seven (23.3%) of MSSA,
MRSA, MSCNS and MRCNS, respectively (Table 1). The phe-
notype cMLSB (ERY-R, CLI-R) was detected respectively, in four
(10.8%) 15 (68.2%), three (21.4%), and 17 (56.7%) of MSSA, MRSA,
MSCNS and MRCNS. The iMLSB phenotype (ERY-R, CLI-S, pos-
itive D test) (Fig. 1) was found in only four (10.8%) of the MSSA
and in one (4.5%) of the MRSA. The MSB phenotype (ERY-R, CLI-
S, negative D test) was detected in two (5.4%), one (4.5%), four
(28.6%), and ﬁve (16.7%) of MSSA, MRSA, MSCNS, and MRCNS,
respectively (Table 1).
For the identiﬁcation of the ermA and ermC genes, 44 iso-
lates with cMLSB and iMLSB phenotypes underwent PCR. Four
(9.1%) isolates showed only ermA gene, 17 (38.6%) had only
ermC gene, one (2.3%) had both genes, and 22 (50%) did not
have the referred genes (Table 2).Discussion
In this study, the frequency of MSSA (25; 67.6%) was greater
than MRSA (ﬁve; 22.7%) and of MSCNS (four; 28.6%) was lower
b r a z j i n f e c t d i s . 2 0 1 
Table 2 – Distribution of ermA  and ermC  genes among
Staphylococcus spp. isolates with MLSB resistance.
Genes Isolates (%)
ermA 4 (9.1)
ermC 17 (38.6)
ermA + ermC 1 (2.3)
None 22 (50.0)
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han MRCNS (seven; 23.3%). In a study conducted in India, 313
solates of Staphylococcus spp. there were 83 (64.84%) MSSA
nd 45 (35.15%) MRSA, in line to the present study; in con-
rast, there were 124 (67.02%) MSCNS and 61 (32.97%) MRCNS.5
 total of 1687 isolates of Staphylococcus spp. investigated in
urkey consisted of 419 (24.8%) MSSA and 464 (27.5%) MRSA,
nlike this study, and the rest of the isolates, similar to
his study, consisted of 196 (11.6%) MSCNS and 608 (36.1%)
RCNS.11
The susceptible phenotype (ERY-S, CLI-S) found in 41
39.8%) isolates in this study prevailed among the isolates
ested. This phenotype was also prevalent in studies carried
ut in India, Libya, and Turkey where the referred phenotype
as detected in 192 (51.5%), 87 (54.7%), and 688 (40.8%) isolates,
espectively.11,20,21
In this study, the 39 (37.9%) cMLSB phenotype isolates pre-
ailed over the ﬁve (4.9%) iMLSB phenotype and over the 12
11.6%) MSB phenotype resistant to macrolides and type B
treptogramins, which is consistent with other studies con-
ucted in Brazil.12,13,22 One of the studies was performed in
ão Paulo revealed 37 (25.17%) and nine (6.12%) isolates with
MLSB and iMLSB phenotypes, respectively, while the MSB was
ot detected.12 Other studies were conducted in the state of
io Grande do Sul; one of them identiﬁed 71 (46.7%), ﬁve (3.3%),
nd ﬁve (3.3%) isolates with cMLSB, iMLSB, and MSB pheno-
ypes, respectively.13 The other study detected 25 (17.9%), 11
7.9%), and two (1.4%) isolates with cMLSB, iMLSB, and MSB
henotypes, respectively.22
In this study the cMLSB phenotype prevailed among the iso-
ates resistant to methicillin, which is consistent with studies
onducted in other countries3,5,11,15,21 as well in Brazil.12,22
The MSB phenotype was more  frequent (12; 11.6%) than the
MLSB (ﬁve; 4.9%) in this study. Diverging from this ﬁnding, the
tudy done by Kumar et al.8 in India found the same frequency
33; 16.9%) of MSB and iMLSB phenotypes among the S. aureus
solates analyzed. Merino-Díaz et al.23 in Spain identiﬁed the
srA gene in all Staphylococcus spp. isolates with MSB pheno-
ype. In Staphylococcus spp. this gene is responsible for an efﬂux
echanism which confers resistance to macrolides and type
 streptogramins, but not to clindamycin.5,24
Only S. aureus showed the iMLSB phenotype and its fre-
uency was higher among the MSSA (four; 10.8%) than among
he MRSA (one; 4.5%) in this study. Astudy conducted in
hicago detected the iMLSB phenotype in 59 (20%) MSSA iso-
ates and in 14 (7%) MRSA isolates in one hospital, and the
MLSB phenotype in 94 (19%) and in 30 (12%) MSSA and MRSA
solates, respectively, in another hospital.25 In a study con-
ucted in Turkey, eight (5.8%) MSSA isolates and two (1.7%)
RSA isolates presented the iMLSB phenotype.26 In the study6;2 0(3):276–281 279
conducted in São Paulo, the iMLSB phenotype was observed
in seven (6.73%) MSSA and in two (4.65%) MRSA isolates.12
These data from previously reported studies are similar to
the ﬁndings of the present study. However, there are other
studies carried out abroad, in which the iMLSB phenotype was
prevalent among MRSA isolates.3,8,15,27,28
Relevant data for antimicrobial susceptibility are signif-
icant in establishing an appropriate therapy; therefore, the
availability of the D test results are important.20,25 Reporting
an isolated Staphylococcus spp. as susceptible to clindamycin
without verifying if it presents inducible resistance, may lead
to inadequate therapy with this drug. In contrast, a negative
result for inducible resistance to clindamycin, conﬁrms the
susceptibility of this antimicrobial, providing a very good ther-
apeutic option.3,8
In this study, the ermA and ermC genes were detected
individually in four (9.1%) and 17 (38.6%) isolates with MLSB
resistance phenotypes, respectively. In some studies, contrary
to this, the ermA gene was identiﬁed more  frequently than
the ermC gene, as in a study conducted in Iran, in which the
ermA and ermC genes were found in 76 (60.3%) and 69 (54.8%) S.
aureus isolates, respectively.29 Schmitz et al.,30 when analyz-
ing S. aureus isolates from 24 European university hospitals
detected the ermA gene in 571 (67%) isolates and the ermC
in 192 (23%). In Korea, Jung et al.31 identiﬁed among 280 S.
aureus isolates, the ermA gene in 250 and the ermC in 14 iso-
lates. In Iran, Moosavian et al.32 detected the ermA and ermC
genes, respectively in 41.1% and 17.7% of the S. aureus isolates
studied.
In other studies, consistent with this, the ermC gene was
predominant relatively to the ermA gene, as in a study from
Spain, in which the ermC gene was more  frequently detected,
in both S. aureus and SCN isolates with constitutive and
inducible phenotypes.23 In Greece, Spiliopoulou et al.33 iden-
tiﬁed the ermA and ermC genes in 22% and 70% of S. aureus
isolates, respectively. Vallianou et al.34 have reported that the
ermC gene was found more  frequently among S. aureus and
SCN isolates of a university hospital also in Greece.
In this study, one (2.3%) isolate presented both ermA and
ermC genes. The association of these genes in Staphylococcus
spp. isolates,29,35,36 was also observed in other studies.
The ermB gene was not investigated, because it is usually
detected in Staphylococcus spp. isolates of animal origin13,23,30
and it is spread mainly between streptococci and enterococci.4
In Rio Grande do Sul, Coutinho et al.13 reported low frequency
of the ermB gene. They found that among 152 Staphylococ-
cus spp. isolates analyzed, 77 had one or more  erm gene, the
ermA, ermC, and ermB genes were found respectively at 49,
29, and three isolates and, the combination of these genes
was found in four isolates,13 data which differed from this
study. However, in a work developed in Texas, with S. aureus
isolates of pediatric origin, among the 67 isolates evaluated,
the ermB gene was identiﬁed in 31 of these, and the ermA
and the ermC genes were detected in 12 and 24 isolates,
respectively.37
Then it was possible to observe the frequency variation of
the phenotypes of the MLSB resistance and of the erm genes
amongst hospitals and geographic regions, already reported by
other authors.13,15,21,29 Therefore, the importance of determin-
ing these frequencies in speciﬁc location is highlighted.13,21
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The good correlation between the phenotypic and geno-
typic methods allows us to infer the mechanism of resistance
to erythromycin and clindamycin, to establish the most
appropriate antimicrobial treatment and to appreciate the epi-
demiological differences in their distribution.23
Conclusion
The ermA gene was less frequent than the ermC gene among
Staphylococcus spp. isolates with cMLSB and iMLSB pheno-
types. Despite the lower frequency of iMLSB than cMLSB and
MSB  phenotypes, it is important to perform the D test in
order to identify it and guide therapeutic procedures. As the
phenotypic and molecular data about a particular mecha-
nism of antimicrobial resistance vary between hospitals and
geographic regions, obtaining local data is useful, since it
can be helpful to emphasize the importance of the imple-
mentation of procedures that aim at controlling the spread
of this mechanism, in the hospital where the study was
conducted.
Conﬂicts  of  interest
The authors declare no conﬂicts of interest.
Acknowledgment
This study was supported by the National Counsel of Techno-
logical and Scientiﬁc Development (CNPq).
 e  f  e  r  e  n  c  e  s
1. Daurel C, Huet C, Dhalluin A, Bes M, Etienne J, Leclercq R.
Differences in potential for selection of clindamycin-resistant
mutants between inducible erm(A) and erm(C) Staphylococcus
aureus genes. J Clin Microbiol. 2007;46:546–50.
2. Fiebelkorn KR, Crawford SA, McElmeel ML, Jorgensen JH.
Practical disk diffusion method for detection of inducible
clindamycin resistance in Staphylococcus aureus and
coagulase-negative staphylococci. J Clin Microbiol.
2003;41:4740–4.
3. Prabhu K, Rao S, Rao V. Inducible clindamycin resistance in
Staphylococcus aureus isolated from clinical samples. J Lab
Physicians. 2011;3:25–7.
4. Leclercq R. Mechanisms of resistance to macrolides and
lincosamides: nature of the resistance elements and their
clinical implications. Clin Infect Dis. 2002;34:482–92.
5. Mahesh CB, Ramakant BK, Jagadeesh VS. The prevalence of
inducible and constitutive clindamycin resistance among the
nasal isolates of Staphylococci. J Clin Diagn Res. 2013;7:1620–2.
6. Drinkovic D, Fuller ER, Shore KP, Holland DJ, Ellis-Pegler R.
Clindamycin treatment of Staphylococcus aureus expressing
inducible clindamycin resistance. J Antimicrob Chemother.
2001;48:315–6.
7. Fokas S, Fokas S, Tsironi M, Kalkani M, Dionysopouloy M.
Prevalence of inducible clindamycin resistance in
macrolide-resistant Staphylococcus spp. Clin Microbiol Infect.
2005;11:337–40.
8. Kumar S, Bandyopadhyay M, Bhattacharya K, et al. Inducible
clindamycin resistance in Staphylococcus isolates from a
2 1 6;2  0(3):276–281
tertiary care hospital in eastern India. Ann Trop Med Public
Health. 2012;5:468–70.
9. Shouval DS, Samra Z, Shalit I, et al. Inducible clindamycin
resistance among methicillin-sensitive Staphylococcus aureus
infections in pediatric patients. Isr Med Assoc J. 2011;13:
605–8.
0. Clinical and Laboratory Standards Institute. Performance
standards for antimicrobial susceptibility testing;
twenty-second informational supplement, M100-S22. Wayne,
PA:  CLSI; 2012.
1. Yilmaz G, Aydin K, Iskender S, Caylan R, Koksal I. Detection
and prevalence of inducible clindamycin resistance in
staphylococci. J Med Microbiol. 2007;56:342–5.
2. Amorim DMR, Person OC, Amaral PJ, Tanaka II. Resistência
induzível à clindamicina entre isolados clínicos de
Staphylococcus aureus.  O Mundo da Saúde. 2009;33:401–5.
3. Coutinho VL, Paiva RM, Reiter KC, de-Paris F, Barth AL,
Machado AB. Distribution of erm genes and low prevalence of
inducible resistance to clindamycin among staphylococci
isolates. Braz J Infect Dis. 2010;14:564–8.
4. Roberts MC, Sutcliffe J, Courvalin P, Jensen LB, Rood J, Seppala
H. Nomenclature for macrolide and
macrolide–lincosamide–streptogramin B resistance
determinants. Antimicrob Agents Chemother.
1999;43:2823–30.
5. Seiﬁ N, Kahani N, Askari E, Mahdipour S, Naderi NM. Inducible
clindamycin resistance in Staphylococcus aureus isolates
recovered from Mashhad, Iran. Iran J Microbiol. 2012;4:82–6.
6. Rabelo MA, Neto AMB, Loibman SO, et al. The occurrence and
dissemination of methicillin and vancomycin-resistant
Staphylococcus in samples from patients and health
professionals of a university hospital in Recife, State of
Pernambuco, Brazil. Rev Soc Bras Med  Trop. 2014;47:437–46.
7. Hu Y, Zhang Q, Meitzler JC. Rapid and sensitive detection of
Escherichia coli O157:H7 in bovine faeces by a multiplex PCR. J
Appl Microbiol. 1999;87:867–76.
8. Lina G, Quaglia A, Reverdy ME, Leclercq R, Vandenesch F,
Etienne J. Distribution of genes encoding resistance to
macrolides, lincosamides, and streptogramins among
staphylococci. Antimicrob Agents Chemother. 1999;43:1062–6.
9. Franc¸a CA, Peixoto RM, Cavalcante MB, et al. Antimicrobial
resistance of Staphylococcus spp. from small ruminant
mastitis in Brazil. Pesq Vet Bras. 2012;32:747–53.
0. Juyal D, Shamanth AS, Pal S, Sharma MK, Prakash R, Sharma
N.  The prevalence of inducible clindamycin resistance among
Staphylococci in a tertiary care hospital – a study from the
Garhwal Hills of Uttarakhand, India. J Clin Diagn Res.
2013;7:61–5.
1. Zorgani A, Shawerf O, Tawil K, El-Turki E, Ghenghesh K.
Inducible clindamycin resistance among staphylococci
isolated from burn patients. Libyan J Med. 2009;4:104–6.
2. Bottega A, Rodrigues MA, Carvalho FA, et al. Evaluation of
constitutive and inducible resistance to clindamycin in
clinical samples of Staphylococcus aureus from a tertiary
hospital. Rev Soc Bras Med Trop. 2014;47:589–92.
3. Merino-Díaz L, Cantos de la Casa A, Torres-Sánchez MJ,
Aznar-Martín J. Detección de resistência inducible a
clindamicina em aislados cutâneos de Staphylococcus spp. por
métodos fenotípicos y genotípicos. Enferm Infecc Microbiol
Clin. 2007;25:77–81.
4. Zelazny AM, Ferraro MJ, Glennen A. Selection of strains for
quality assessment of the disk induction method for
detection of inducible clindamycin resistance in
staphylococci: a CLSI collaborative study. J Clin Microbiol.
2005;43:2613–5.5. Schreckenberger PC, Ilendo E, Ristow KL. Incidence of
constitutive and inducible clindamycin resistance in
Staphylococcus aureus and coagulase-negative staphylococci in
 2 0 1 
2
2
2
2
3
3
3
3
3
3
3
3b r a z j i n f e c t d i s .
a community and a tertiary care hospital. J Clin Microbiol.
2004;42:2777–9.
6. Tekin A, Dal T, Deveci O, Tekin R, Atmaca S, Dayan S.
Assessment of methicillin and clindamycin resistance
patterns in Staphylococcus aureus isolated from a tertiary
hospital in Turkey. Infez Med. 2013;21:111–6.
7. Shrestha B, Pokhrel BM, Mohapatra TM. Phenotypic
characterization of nosocomial isolates of Staphylococcus
aureus with reference to MRSA. J Infect Dev Ctries.
2009;3:554–60.
8. Phukan C, Ahmed GU, Sarma PP. Inducible clindamycin
resistance among Staphylococcus aureus isolates in a tertiary
care hospital of Assam. Indian J Med Microbiol. 2015;33:
456–8.
9. Saderi H, Emadi B, Owlia P. Phenotypic and genotypic study of
macrolide, lincosamide and streptogramin B (MLSB)
resistance in clinical isolates of Staphylococcus aureus in
Tehran, Iran. Med Sci Monit. 2011;17:48–53.
0. Schmitz FJ, Sadurski R, Kray A, et al. Prevalence of
macrolide-resistance genes in Staphylococcus aureus and
Enterococcus faecium isolates from 24 European university
hospitals. J Antimicrob Chemother. 2000;45:891–4.1. Jung YH, Kim KW, Lee KM, et al. Prevalence and
characterization of macrolide–lincomycin–streptogramin
B-resistant Staphylococcus aureus in Korean hospitals. J
Antimicrob Chemother. 2008;61:458–60.6;2 0(3):276–281 281
2. Moosavian M, Shoja S, Rostami S, Torabipour M,
Farshadzadeh Z. Inducible clindamycin resistance in clinical
isolates of Staphylococcus aureus due to erm genes, Iran. Iran J
Microbiol. 2014;6:421–7.
3. Spiliopoulou I, Petinaki E, Papandreou P, Dimitracopoulos G.
erm(C)  is the predominant genetic determinant for the
expression of resistance to macrolides among
methicillin-resistant Staphylococcus aureus clinical isolates in
Greece. J Antimicrob Chemother. 2004;53:814–7.
4. Vallianou N, Evangelopoulos A, Hadjisoteriou M,  Avlami A,
Petrikkos G. Prevalence of macrolide, lincosamide, and
streptogramin resistance among staphylococci in a tertiary
care hospital in Athens, Greece. J Chemother. 2014;27:319–23.
5. Yildiz O, C¸ oban AY, Sener AG, et al. Antimicrobial
susceptibility and resistance mechanisms of methicillin
resistant Staphylococcus aureus isolated from 12 hospitals in
Turkey. Ann Clin Microbiol Antimicrob. 2014;13:44.
6. Aleksandra AD, Misic MS, Mira ZV, et al. Prevalence of
inducible clindamycin resistance among
community-associated staphylococcal isolates in central
Serbia. Indian J Med Microbiol. 2014;32:49–52.
7. Chavez-Bueno S, Bozdogan B, Katz K, et al. Inducible
clindamycin resistance and molecular epidemiologic trends
of  pediatric community-acquired methicillin-resistant
Staphylococcus aureus in Dallas, Texas. Antimicrob Agents
Chemother. 2005;49:2283–8.
